ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 714

The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study

Majed Khraishi1, Rana Aslanov2, Sanjay Dixit3, Ramin Yazdani4, Vandana Ahluwalia5 and Sarah Khraishi6, 1Nexus Clinical Research, St John's, NF, Canada, 2Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada, 3McMaster University, Hamilton, ON, Canada, 4Rheumatology, St. Clare' Mercy Hospital, St. John's, NF, Canada, 5Rheumatology, William Osler Health Center, Brampton, ON, Canada, 6NL Research Technologies (NLRT), St. John's, NF, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies

Session Type: Abstract Submissions (ACR)

Background/Purpose

In our centre, new tools for the assessment of SLE activity: the  Lupus Activity Scoring Tool (LAST) and Clinical Lupus Activity Scoring Tool (C-LAST) were developed and validated. We aimed to validate the LAST and C-LAST in multiple clinical settings using their  correlation to the SELENA SLEDAI modification, and to investigate the correlation of the specific components of the LAST (e.g. patient’s and physician’s global assessments of disease activity, steroid use) to the SS.

Methods

This multicenter study was initiated in five Canadian clinics: 3 in Newfoundland and 2 in Ontario. The LAST includes patient (PGA)and physician global assessment of disease activity (PHGA), C3, C4 and Anti-ds Anti-DNA titer abnormalities, and a formula incorporating the current immunomodulating medication. The C-LAST does not include laboratory test results. Patients who met the SLE ACR 1997 criteria update were  recruited and evaluated in the study centres using LAST/C-LAST. Some of the patients were prospectively followed and evaluated by the same tools at each visit. The SS was also calculated for each visit.

Results

Fifty-eight patients (84.5% females) with 98 assessments from five study centers were included in this analysis. The median age was 49.0 (Q1-Q3=33.8-60.3) years with the mean (SD) disease duration 12.1 (6.5) years. Scores from the LAST/C-LAST were obtained at each visit in addition to the SLEDAI scores. The mean (SD) SLEDAI score was 8.2 (5.2). The mean (SD) LAST (with C3, C4 and Anti-ds Anti-DNA) score was 30.5 (17.3) and C-LAST – 32.2 (20.1). The SS scores were consistent and strongly correlated with the LAST and C-LAST scores (r=0.430, p<0.001 & r=0.215, p=0.034, respectively) at the baseline and follow-up visits: SS scores 0-4 corresponded to the LAST scores of 0-30 while SS scores of 8 or higher corresponded to 50 and higher, respectively. Both SS and LAST scores were significantly correlated with current treatment with Prednisone (r=0.305, p=0.002 & r=0.430, p<0.001, respectively); LAST score was also correlated with Mycophenolate mofetil (r=0.205, p=0.043) and Azathioprine (r=0.296, p=0.003) treatments. Patient’s (PGA) and Physician’s (PHGA) Global Assessments of SLE activity were strongly correlated with each other (r=0.759, p<0.001) and with the LAST score (r=0.781, p<0.001 & r=0.826, p<0.001, respectively); PHGA was also significantly correlated with SELENA SLEDAI score (r=0.324, p=0.001). The LAST and C-LAST scores concurred in 90% of the assessments with r=0.898 and p<0.001.

We utilized an electronic application of the LAST which was easy to use and no errors were found with its results as compared to the manually obtained scores with the Pearson’s correlation coefficient r=0.995 & p<0.001.

Conclusion

The Lupus Activity Scoring Tool (LAST) and C-LAST are new disease activity indices that correlate well with the SELENA SLEDAI modification. The use of simple clinical variables as a measure of SLE activity seems to be valid under different clinical settings with different assessors. The inclusion of patient’s global assessment and the current use of steroids and immunomodulators can be utilized effectively in assessing disease activity.


Disclosure:

M. Khraishi,

Research grant,

2;

R. Aslanov,
None;

S. Dixit,
None;

R. Yazdani,
None;

V. Ahluwalia,
None;

S. Khraishi,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-validity-of-patient-and-physician-global-disease-activity-assessments-of-systemic-lupus-erythematosus-results-from-the-lupus-activity-scoring-tool-last-as-compared-to-the-selena-sledai-ss-mod/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.